Mike Moore interviews Alessandro Grillini (Founder/CEO/CTO), Reyedar.  Early detection of visual & neurodegenrative diseases is crucial because they often develop asymptomatically while causing irreversible damage. However, current screening methods for these conditions are frequently time-consuming, invasive, or unreliable, placing a strain on healthcare systems.

Reyedar addresses this problem by combining eye-tracking technology and Deep Learning to collect biomarkers of people’s visual and neurological health effortlessly. Eye movements are controlled by a complex network of ocular and brain structures. Subtle alterations in eye movement behavior can indicate the presence of underlying medical conditions.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health